The Chemotherapy Foundation, Inc. – Trademark Portfolio

Entity Type: 03

The Chemotherapy Foundation, Inc. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include CHEMOTHERAPY FOUNDATION SYMPOSIUM INNOVATIVE CANCER THERAPY FOR TOMORROW. The owner is based in New York, NY.

Suite 403

183 Madison Avenue

New York, NY 10016

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

The Chemotherapy Foundation, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does The Chemotherapy Foundation, Inc. have?

The Chemotherapy Foundation, Inc. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does The Chemotherapy Foundation, Inc. file in?

The Chemotherapy Foundation, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 41 (Education & Entertainment). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are The Chemotherapy Foundation, Inc.'s most well-known trademarks?

The Chemotherapy Foundation, Inc.'s registered trademark portfolio includes well-known marks such as CHEMOTHERAPY FOUNDATION SYMPOSIUM INNOVATIVE CANCER THERAPY FOR TOMORROW. These are among 1 currently registered trademark in the portfolio.

What is The Chemotherapy Foundation, Inc.'s trademark registration success rate?

The Chemotherapy Foundation, Inc. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.